As per the recently published report by MarketsandMarket™, The report "Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028", is projected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Browse
- 182
Market Data Tables
- 44
Figures
- 245
Pages and in-depth TOC on "Preimplantation Genetic
Testing Market - Global Forecast to 2028”
Some of the prominent key players are:
- Illumina,
Inc. (US),
- Thermo
Fisher Scientific Inc. (US),
- Agilent
Technologies, Inc. (US),
- Revvity
(US),
- The
Cooper Companies, Inc. (US), and many more......
Mergers
& acquisitions, investments & expansions, partnerships &
collaborations, and new product developments are some of the major strategies
adopted by these key players to enhance their positions in
the Preimplantation Genetic Testing Market.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605
- Preimplantation
genetic screening, or aneuploidy screening, involves screening embryos for
the assessment of aneuploidy. This segment is expected to dominate the
global preimplantation genetic testing market during the forecast period,
driven by a decrease in female fertility with rising maternal age, better
implantation rate and reduced IVF cycle times.
- Based
on the products, the global preimplantation genetic testing market is
broadly segmented into instruments, reagents & consumables, and
software & services. The expanding applications of specific
technologies (such as NGS and aCGH for whole-genome sequencing and FISH in
the diagnosis of specific genetic disorders).
- By end
user, the global preimplantation genetic testing market is broadly
segmented into hospitals, diagnostic labs, fertility clinics, and other
end users. The large share of this segment can be attributed to factors
such as the increasing number of fertility centers globally, the high
success rate of treatment in fertility centers, and growing medical
tourism in developing countries.
- Based
on the region, the preimplantation genetic testing market is segmented
into North America, Europe, Asia Pacific, and the Rest of the World. The
North American market is driven by high incidence of chromosomal
disorders, and an increasing number of awareness programs.
The new research study
consists of industry trends, pricing analysis, patent analysis, conference and
webinar materials, key stakeholders, and buying behaviour in the market. The
growth in this market is attributed to the increasing demand for assisted reproductive
technologies, rising maternal age trends, and ongoing research and development
in the field of genetics. On the other hand, socio-ethical concerns surrounding
preimplantation genetic testing may challenge the growth of market. Whereas,
use of fertility treatment options by single parents and same-sex couples
provides growth opportunities for market.
No comments:
Post a Comment